Empfohlen
Weitere ähnliche Inhalte
Was ist angesagt?
Was ist angesagt? (20)
Andere mochten auch
Andere mochten auch (15)
Ă„hnlich wie Inovio Pharmaceuticals, Inc. Corporate Presentation December 2013
Ă„hnlich wie Inovio Pharmaceuticals, Inc. Corporate Presentation December 2013 (20)
Mehr von Company Spotlight
Mehr von Company Spotlight (20)
KĂĽrzlich hochgeladen
KĂĽrzlich hochgeladen (20)
Inovio Pharmaceuticals, Inc. Corporate Presentation December 2013
- 1. Revolutionizing Vaccines Dr. J. Joseph Kim President & CEO NYSE MKT: INO
- 2. Forward Looking Statement Our commentary and responses to your questions may contain forward-looking statements, including comments concerning clinical trials and product development programs, evaluation of potential opportunities, the level of corporate expenditures, the assessment of Inovio’s technology by potential corporate partners, capital market conditions, timing of events, cash consumption and other subjects. Information concerning factors that could cause actual results to differ materially from those set forth in our Annual Report on Form 10-K for the year ended December 31, 2012, our Form 10-Q for the quarter ended September 30, 2013 and other regulatory filings from time to time. 2
- 3. Roche Partnership • Collaborating with a global leader in innovative cancer drugs • Develop and commercialize Inovio’s prostate cancer (INO5150) and hepatitis B (INO-1800) immunotherapies • $10 million up-front payment • $412.5 million milestone payments for development and commercial events • Roche may pay other development milestone payments if it pursues other indications with INO-5150 or INO-1800 • Roche to fund all ongoing development costs • Up to double-digit royalties on sales of a marketed product 3
- 4. T cells: Inovio Commands the Body’s SWAT Team Infected cell • Are safe and tolerable • Requires a directive to attack T cell Cytotoxic T lymphocyte 4 Provided by Dr. Philip Greenberg Hutchinson Cancer Research Center
- 5. Inovio’s Technology Inovio’s Technology • Synthetic DNA vaccines • Electroporation delivery • Best-in-class immune responses Plasmids Electroporation device 5 • Favorable safety profile • Over 400 patents
- 6. The Basis For How We Stimulate T-cells Antigen Y Select important common antigen(s), which body recognizes as foreign and relates to a cancer or infected cell Antigen Y Strain 2 Antigen Y Strain X 6 Strain 1 Choose important strains/variants of target virus/cancer
- 7. The Basis For How We Stimulate T-cells Antigen Y Antigen Y Antigen Y Strain 2 Strain X Identify gene sequence of selected antigen(s) from chosen strains/variants of the virus/cancer Strain 1 Synthetically create optimal consensus gene sequence for the selected antigen 7
- 8. The Basis For How We Stimulate T-cells Insert SynCon® gene sequence for selected antigen into DNA plasmid Antigen consensus sequence SYNCON® DNA SynCon DNA plasmid ready to manufacture 8 DNA Plasmid
- 9. The Basis For How We Stimulate T-cells DNA vaccine delivered into muscle or skin Antibodies or killer T-cells that can eliminate cancerous or infected cells are produced 9 Electroporation: millisecond electrical fields applied Antigen-presenting cells engulf the antigens and carry them to lymph nodes Temporary pores in cell membrane; significant cellular uptake of vaccine Cell membrane reseals. Cellular machinery uses the DNA code to produce one or more of the targeted disease antigens
- 10. Better Delivery = Enhanced Gene Expression 1000x enhancement in cellular uptake > 10-100x enhancement in immunogenicity Intramuscular 10 Ref: Sardesai & Weiner Curr. Opin. Immunol. 2011 Intradermal
- 11. #1 in Accelerating and Driving T Cell Responses “Immunotherapy against HPV 16/18 generates potent TH1 and cytotoxic cellular immune responses” October 10, 2012 “Safety and comparative immunogenicity of an HIV-1 DNA vaccine in combination with plasmid Interleukin 12 and impact of intramuscular electroporation for delivery” July 8, 2013 11
- 12. Broad Medical and Market Opportunities Product Name Indication Preclinical Vgx-3100 Cervical dysplasia Therapeutic INO-3112 Cervical Cancer Therapeutic INO-3112 Head & Neck Cancer Phase I Therapeutic Ino-5150 Prostate cancer Ino-1400 Breast/lung cancers pennvax® hiv Preventive/Therapeutic Ino-3510 influenza Preventive Ino-8000 Hepatitis C Therapeutic ino-1800 Hepatitis B Therapeutic MaV-12 malaria Preventive 12 INTERNALLY FUNDED Therapeutic Therapeutic EXTERNALLY FUNDED Phase II Phase III
- 13. Inovio’s Lead Program VGX 3100: • Capitalizes on Inovio’s ability to generate T cells • Immunotherapy for pre-cancers and cancers caused by human papillomavirus (HPV) • Phase II on-going: high grade cervical precancers (CIN 2/3 dysplasia) • Projected efficacy data: mid-2014 13
- 15. VGX-3100: Phase I Study Data Inovio’s Lead Program • Strong T-cell response in 14 of 18 (78%) vaccinated subjects at month 4 • 83% response rate in highest dose group 15 *Immunotherapy against HPV16/18 generates potent TH1 and cytotoxic cellular immune responses. Sci Transl Med. 2012 Oct; 4:155ra13. dOI:10.1126/scitranslmed.3004414
- 16. Inovio’s Lead Program Phase I trial results for vgx-3100 • • 16 9 month durability of robust T cell response in 12/14 responders • 10/11 responders showed killing effect against target cells Safe & well tolerated Source: Science Translational Medicine Oct. 2012
- 18. Broad Medical and Market Opportunities HPV product franchise planning • CIN 2/3 Phase III • Other HPV-related indications: initiate Phase IIs • Orphan designation potential 18
- 19. Strategy • Build on proof-ofconcept studies with phase I/II clinical trials • Spread cost/risk with: o Non-dilutive partner funding o R&D grants o “Sponsored” clinical trials • May partner or license out products for further development and commercialization 19
- 20. Broad Base of Support for Inovio • • • • Universities Government Foundations Corporate partnerships Almost $60M in funding since 2009 20
- 21. Broad Base of Support for Inovio 21
- 22. power of our people 22 • Management • Board of Directors • Scientific Advisory Board
- 23. Management J.Joseph Kim, PhD President & CEO • Decades of biotechnology/pharma management • Merck: hepatitis A and B vaccines manufacturing; HIV vaccine (Ad5) R&D Niranjan Y. Sardesai, PhD COO • Extensive biotech management and product development experience • Led development of diagnostics for mesothelioma, bladder cancer, and ovarian cancer for Fujirebio Diagnostics 23 Peter Kies CFO • Ernst & Young • Experience with growth companies anthrax Louis Pasteur Mark L. Bagarazzi, MD CMO • Clinical research experience incl. Merck • Led clinical/regulatory for shingles and rotavirus vaccines; DNA vaccine expert
- 24. Board of Directors Morton Collins, PhD Avtar Dhillon, MD • General Partner, Battelle Ventures and Innovations Valley Partners Chairman, BOD • Former President & CEO, Inovio Biomedical Simon X. Benito • Former Senior Vice President, Merck Vaccine Division Angel Cabrera, PhD • President, George Mason University • Former President, Thunderbird School of Global Management 24 anthrax Louis Pasteur J.Joseph Kim, PhD • President & CEO, Inovio Adel Mahmoud, PhD • Professor, Princeton University • Former President, Merck Vaccines • Responsible for Gardasil®, Zostavax®, Proquad® and Rotateq®
- 25. Scientific Advisory Board Philip Greenberg, MD David B. Weiner, PhD • Expert in T-cell immunology • Head, Immunology Program, Fred Hutchinson Cancer Research Center Chairman •“Father of DNA vaccines” • Dept. of Pathology & Laboratory Medicine, University of Pennsylvania Thomas S. Edgington, MD • Founded multiple biotech companies; extensively published • Emeritus Professor, Scripps Research Institute Anthony W. Ford-Hutchinson, PhD • Former SVP, Vaccines R&D, Merck • Oversaw development: Singulair®, Januvia®, Gardasil®, Zostavax®, Proquad® and Rotateq® 25 anthrax Louis Pasteur Stanley A. Plotkin, MD • Developed rubella and rabies vaccines • Oversaw Sanofi flu vaccine • Emeritus Professor, Wistar Institute & University of Pennsylvania
- 27. Financial Information Cash, cash equivalents & short-term investments1 Additional cash raised2 NYSE MKT: INO $ 46.3 M $ 11.1 M Debt1 0M $1.98 1Q 2016 Cash runway Issued & outstanding shares2 208.4 M $1.98 Recent price3 $412.6 M Market cap3 1Sep. 27 30, 2013 2Nov. 12, 2013 3 Dec. 9, 2013 11/9/2013 12/9/2013
- 29. Upcoming Value Drivers Vgx-3100 INO-3112 INO-3112 Ino-5150 Ino-1400 29 INTERNALLY FUNDED Cervical dysplasia Mid-2014 Phase II study data Cervical Cancer 1H 2014 Initiate phase I/IIa Head & Neck Cancer 1H 2014 Initiate phase I/IIa Prostate cancer 1H 2014 Initiate phase I/IIa Breast/lung Cancer EXTERNALLY FUNDED 2014 Initiate phase I/IIa
- 30. Upcoming Value Drivers PennVAX® Ino-1800 MAV-12 Ino-8000 30 INTERNALLY FUNDED HIV 1H 2014 Initiate PENNVAX -GP phase I study Hepatitis B 2014 Prepare phase I/IIa Malaria 2014 Initiate phase I/IIa Hepatitis C 2015 Report phase I data EXTERNALLY FUNDED
- 31. The Opportunity Investor Highlights • Break-through immune therapy with the power to save lives and maximize shareholder value • Targeting broad range of diseases and billion dollar markets • Best-in-class T cells to prevent, treat & cure cancers and infectious diseases • Phase II efficacy data coming • Validating partnership with Roche 31
- 32. Investor Contact investor contacts Bernie Hertel Senior Director, Corporate Communications 858-410-3101 ď‚ź bhertel@inovio.com 32